# Nutex Health Inc.: Form 10-Q/A for the period ended Jun 30, 2020

- Company: [Nutex Health Inc.](/companies/nutx.md) (CIK 1479681)
- Form: 10-Q/A
- Filed: 2020-08-24
- Accepted by EDGAR: Aug 21, 2020, 21:06 ET
- Period: 2020-06-30
- Accession: 0001607062-20-000246
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1479681/000160706220000246/clnh063020form10qa.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479681/000160706220000246/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-04-01 to 2020-06-30 | $378.6k | us-gaap:Revenues |
| Revenue | 6 months, 2020-01-01 to 2020-06-30 | $844.2k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-04-01 to 2020-06-30 | $264.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2020-01-01 to 2020-06-30 | $464.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-04-01 to 2020-06-30 | $113.7k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2020-01-01 to 2020-06-30 | $380.2k | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-04-01 to 2020-06-30 | $314.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2020-01-01 to 2020-06-30 | $429.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2020-04-01 to 2020-06-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2020-01-01 to 2020-06-30 | −$2.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-04-01 to 2020-06-30 | $249.3k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2020-01-01 to 2020-06-30 | $314.3k | us-gaap:InterestExpense |
| Net income | 3 months, 2020-04-01 to 2020-06-30 | $2.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2020-01-01 to 2020-06-30 | $1.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-04-01 to 2020-06-30 | $0.59 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2020-01-01 to 2020-06-30 | $0.35 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2020-01-01 to 2020-06-30 | −$1.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2020-01-01 to 2020-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-06-30 | $63.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-06-30 | $365.0k | us-gaap:AssetsCurrent |
| Total assets | at 2020-06-30 | $7.2m | us-gaap:Assets |
| Current liabilities | at 2020-06-30 | $1.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-06-30 | $1.4m | us-gaap:Liabilities |
| Long-term debt | at 2020-06-30 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | at 2020-06-30 | $5.8m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1479681/000160706220000246/clnh063020form10qa.htm

Filed Aug 24, 2020.
Source: SEC EDGAR, the filing index for accession 0001607062-20-000246. Last ingested by Listed: Nov 14, 2026, 12:46 ET. No prices; not investment advice.
